Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

ENMD-2076

250 mg per day in oral capsules in 28 day continuous cycles

Trial Locations (3)

46202

Inidiana University Melvin and Bren Simon Cancer Center, Indianapolis

80045

University of Colorado Cancer Center, Aurora

100021

Cancer Hospital of Chinese Academy of Medical Science, Beijing

Sponsors
All Listed Sponsors
collaborator

University of Colorado, Denver

OTHER

collaborator

Indiana University Melvin and Bren Simon Cancer Center

OTHER

lead

CASI Pharmaceuticals, Inc.

INDUSTRY